CNBC’s Jim Cramer delivers his daily Mad Dash.
Explore the revolutionary potential of biotechnology and gene editing, alongside crucial ethical considerations and ...
In South San Francisco, Genentech showed that recombinant DNA technology could transform medicine and create therapies once ...
Morgan Stanley said the recent weakness in U.S. semiconductor stocks is a sign that the market gains are broadening, with ...
Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced it will host a live webcast ...
The artificial intelligence buildout has run headlong into a physical bottleneck: electricity. Data centers are demanding ...
IBB, one of the largest exchange-traded funds focused on biotechnology, manages approximately $8.28 billion in assets and ...
As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.
The FDA is fast-tracking Regeneron's planned drug facility in Saratoga County through a new federal pilot program. The ...
New Corporate Identity Reflects Strategic Transition into AI Energy Infrastructure Equipment & Services Sector Following Acquisition of NOMAD Transportable Power Systems -- BOCA RATON, Fla., July 06 ...
A Congressional investigation is looking into whether drug trials in China that involved U.S. companies possibly took place ...
Morgan Stanley says U.S. equity-market leadership is beginning to expand beyond the semiconductor and AI infrastructure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results